Human epididymis protein 4: The start of a post-ROMAn era?

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2069-2073

  Melichar, Bohuslav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; GAMMA INTERFERON; GUANOSINE; HUMAN EPIDIDYMIS PROTEIN 4; NEOPTERIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PTERIDINE;

ADVANCED CANCER; ASCITES FLUID CYTOLOGY; ATHEROSCLEROSIS; BREAST CANCER; BREATH ANALYSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ECHOGRAPHY; ENDOMETRIUM CANCER; GASTROINTESTINAL TUMOR; GENE MUTATION; HEALTH CARE DELIVERY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; LAPAROSCOPIC SURGERY; LAPAROTOMY; LIVER CIRRHOSIS; LUNG CANCER; LYMPH VESSEL METASTASIS; MENOPAUSE; MULTIMODALITY CANCER THERAPY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PATIENT CARE; PERCUTANEOUS BIOPSY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VOLUME; URINALYSIS; VAGINA BLEEDING;

ALGORITHMS; BIOLOGICAL MARKERS; EPIDIDYMIS; HUMANS; MALE; PROTEINS;

EID: 84872863691     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0683     Document Type: Review

References (46)

1. Melichar B, Plebani M. Laboratory medicine: an essential partner in the care of cancer patients. Clin Chem Lab Med 2011; 49:1575-8.
2. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup M, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
3. Melichar B, Fridrichova P, Tomsova M, Malirova E. Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy. Eur J Gynaecol Oncol 2009;30:323-5.
4. Bristow RE, Palis BE, Chi DS, Cliby WA. The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol Oncol 2010;118: 262-7.
5. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2011;49:443-5.
6. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
7. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati G, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521-5.
8. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Furst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011;49:2081-8.
9. Plebani M. HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med 2012;50:2127-36.
10. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
11. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228.e1-6.
12. Melichar B, Urminská H, Kohlová T, Nová M, Cesák T. Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol 2004;94:267-76.
13. Kalabova H, Melichar B, Ungermann L, Dolezal J, Krcmova L, Kasparova M, et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011;28:1281-7.
14. Kralickova P, Kalabova H, Krcmova L, Kasparova M, Plisek J, Ungermann L, et al. Correlation of peripheral blood CD 14 + 16 + monocytes, urinary neopterin and the risk factors of atherosclerosis in patients with breast carcinoma. Pteridines 2011;22:66-72.
15. Melichar B, Laco J, Fridrichova P, Simkovic M, Papajik T, Foretova L. Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases. Acta Oncol 2012;51:136-8.
16. Rustin GJS, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.
17. Fleming NC, Cass H, Walsh CS, Karlan BY, Li AJ. CA125 surveillace increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 2011;121:249-52.
18. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen M, Baron B, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the Intergroup Trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006;24:45-51.
19. Trape J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer A, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011;49:1605-20.
20. Hertlein L, Stieber P, Kirschenhofer A, Furst S, Mayr D, Hofman K, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med 2012;50:2181-8.
21. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012;50:2189-98.
22. Poumpouridou N, Kroupis C. Hereditary breast cancer: beyond BRCA genetic analysis. Clin Chem Lab Med 2012;50: 423-34.
23. Vietri MT, Molinari AM, De Paola ML, Cantile F, Fasano M, Cioffi M. Identification of novel in-frame deletion in BRCA2 and analysis of variants of BRCA 1/2 in Italian patients affected with hereditary breast and ovarian cancer. Clin Chem Lab Med 2012;50:2171-80.
24. Rubin SC, Benjamin I, Benbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
25. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. J Am Med Assoc 2000;283:2260-5.
26. Cass I, Baldwin RL, Varkes T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
27. Chetrit A, Hirsch-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5.
28. Tomsova M, Melichar B, Sedlakova I, Steiner I. Prognostic significance of CD3 + tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108:415-20.
29. Melichar B, Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3-17.
30. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 2003;13:435-43.
31. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and, immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003;9: 5228-37.
32. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006;16: 240-52.
33. Hammerer-Lercher A, Moser C, Leichtfried V, Schobersberger W, Griesmacher A, Fuchs D. Comparison of a commercial urinary neopterin radioimmunoassay with high performance liquid chromatography. Clin Chem Lab Med 2012;50:1075-8.
34. Moutereau S, Ech Chad N, Devanlay M, Esmilaire L, Loric S. Improved neopterin ELISA kit: a good compromise between HPLC results and clinical practice. Clin Chem Lab Med 2011;49:553-4.
35. Melichar B, Gregor J, Solichova D, Lukes J, Tichy M, Pidrman V. Increased urinary neopterin in acute myocardial infarction. Clin Chem 1994;40:338-9.
36. Montagnana M, Lippi G, Danese E, Salvagno GL, Cervellin G, Guidi GC. Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I. Clin Chem Lab Med 2012;50:747-8.
37. Plata-Nazar K, Jankowska A. Clinical usefulness of determining the concentration of neopterin. Pteridines 2011;22:77-89.
38. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190-8.
39. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest 2001;61:363-70.
40. Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, et al. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996;82:218-20.
41. Melichar B, Kalabova H, Krcmova L, Kasparova M, Plisek J, Cerman J, et al. Urinary neopterin in patients with metastatic colon cancer treated with patupilone. Pteridines 2011;22:61-5.
42. Melichar B, Kalabova H, Urbanek L, Malirova E, Solichova D. Serial urinary neopterin measurements reflect the disease course in patients with epithelial ovarian carcinoma treated with paclitaxel/platinum. Pteridines 2007;18:1-7.
43. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-27.
44. Zimmermann R, Weisbach V, Eckstein R. Choice of sample for the analysis of circulating angiogenic cytokines. Clin Chem Lab Med 2008;46:1328.
45. Gabrilovich DI, Chen HL, Girgis KR, Cunningham T, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
46. Melichar B, Kalabova H, Krcmova L, Kasparova M, Plisek J, Hyspler R, et al. Urinary neopterin, serum retinol, alphatocopherol and homocysteine in breast cancer patients during treatment with bevacizumab and chemotherapy. Pteridines 2010;21:87-93.